Implementing BYOD Across Phase II and III Clinical Trials

The significant advantages for electronic patient-reported outcomes (ePRO) over paper records include improved compliance, data quality and patient experiences – these advantages will best be realized only when Bring Your Own Device (BYOD) for the collection of patient-reported outcomes is deployed across all trial phases. In practice, however, implementation of BYOD has been mostly isolated to Phase I and Phase IV trials. 

Regardless, there are real opportunities now for bringing the promise of BYOD to Phase II and III. This webinar will review strategies and outcomes from a recent Phase III study supported by Clinical Ink, where BYOD was leveraged by 90 percent of its patient population for the collection of primary endpoint data, achieving a compliance rate well over 90 percent. The featured speaker in this webinar will also provide real-world examples for how other Phase II and III studies can also use BYOD for data collection.

Speaker

Gena Gough, MBA, PMP, Project Director, ePRO and Engagement, Clinical Ink

Gena Gough is a project management professional with over 20 years of experience in project management applied to pharmaceutical clinical trials, electronic clinical outcomes assessments (eCOA), non-profit health care systems and academic medical centers. She serves as a subject matter expert for ePRO/eCOA, engagement services and technology standards, bringing more than a decade of ePRO/eCOA experience garnered across direct management of over 75 Phase II/III trials. Further, Gena represents Clinical Ink as a member representative in the ePRO Consortium.

Message Presenter